<DOC>
	<DOCNO>NCT00027937</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Biological therapy interleukin-2 use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase II trial study effectiveness combination chemotherapy , peripheral stem cell transplantation , interleukin-2 treating patient solid tumor lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Peripheral Stem Cell Transplantation , Biological Therapy Treating Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity sargramostim ( GM-CSF ) filgrastim ( G-CSF ) -mobilized interleukin-2 ( IL-2 ) -incubated autologous peripheral blood stem cell sequential IL-2 patient solid tumor lymphoma . - Determine ability cyclophosphamide paclitaxel follow GM-CSF G-CSF mobilize adequate number CD34+ cell immune cell patient . - Determine time neutrophil platelet engraftment patient treat regimen . - Determine overall disease-free survival patient treat regimen . OUTLINE : Patients receive cyclophosphamide IV 1-2 hour day 1 paclitaxel IV 4 hour day 2 . Patients also receive sargramostim ( GM-CSF ) subcutaneously ( SC ) alone day 3-9 GM-CSF filgrastim ( G-CSF ) SC begin day 10 continue leukapheresis complete . Patients receive high-dose chemotherapy comprise oral busulfan every 6 hour day -8 -6 , melphalan IV day -5 -4 , thiotepa IV day -3 -2 . Autologous peripheral blood stem cell ( PBSC ) treat ex vivo interleukin-2 ( IL-2 ) day -1 . Patients undergo IL-2-treated autologous PBSC transplantation day 0 . Beginning 4 hour PBSC transplantation , patient receive IL-2 IV continuously 5 day . IL-2 therapy repeat every 7 day 4 course . Patients follow day 60-80 , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor , Hodgkin 's lymphoma , Bcell nonHodgkin 's lymphoma Eligible autologous stem cell transplantation No pleural effusion , pericardial effusion , ascites No Tcell lymphoma PATIENT CHARACTERISTICS : Age : Under 57 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL ( unless due Gilbert 's disease ) SGOT SGPT great 2 time upper limit normal Hepatitis B C negative Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 50 % No congestive heart disease No history myocardial infarction within past year No coronary artery disease No history arrhythmia Pulmonary : Diffusion capacity ( correct ) least 60 % FEV_1 least 65 % predict Other : HIV negative No history seizures No mental disorder require medication ( e.g. , haloperidol ) No active connective tissue disease No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ No allergy gentamicin No hypersensitivity E. coliderived preparation No history severe allergy sargramostim ( GMCSF ) filgrastim ( GCSF ) No systemic infection Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : No concurrent corticosteroid therapy Radiotherapy : Not specify Surgery : Not specify Other : No contrast dye 3 week completion interleukin2 therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>